ライフサイエンスコーパス: patient adherence

1 pill burdens and costs as well as improving patient adherence.

2 ejection fraction and the conundrum of poor patient adherence.

3 % CI, 1.11-1.41) were associated with better patient adherence.

4 2; P = .028) were negatively associated with patient adherence.

5 erapies can prevent resistance regardless of patient adherence.

6 that have yet to be assessed in relation to patient adherence.

7 ch program ultimately depends on quality and patient adherence.

8 strategies to improve provider practices and patient adherence across health sectors are urgently nee

9 present actionable opportunities to optimize patient adherence and clinical outcomes.

10 ulosis treatment could significantly improve patient adherence and decrease the development of drug r

11 s reveals that even in conditions of perfect patient adherence and drug penetration a substantial lev

12 e long treatment duration (resulting in poor patient adherence and loss of patients to follow-up), co

13 Addressing both patient adherence and provider intensification simultane

14 d the prevalence of and relationship between patient adherence and provider treatment intensification

15 ities and socioeconomic barriers often limit patient adherence and self-management with hemodialysis.

16 ve shown that there is a correlation between patient adherence and treatment outcomes.

17 ght be reduced through improvements in care, patient adherence, and communication.

18 Strategies that foster greater patient adherence are also identified.

19 Additional effort is required to ensure patient adherence, as well as additional support to clin

20 therapies in the 30 days after discharge and patient adherence at 12 months after discharge, adjustin

21 Patient adherence contributed to 44% of patients with mi

22 Electronic monitoring of patient adherence documented that a sizable number of pa

23 of antiretroviral therapy (ART) include poor patient adherence, drug toxicities, viral resistance, an

24 ims and modalities of management; suboptimal patient adherence, even to demonstrably effective therap

25 n contact and satisfaction, quality of life, patient adherence, hospitalizations, and mortality.

26 ion discrepancies, number of medications and patient adherence identified in this study.

27 esearch has been done on the problem of poor patient adherence in pediatric chronic illnesses, the pr

28 Patient adherence is critical in evaluating the effectiv

29 conceptual framework of factors that affect patient adherence is presented.

30 ntraocular pressure (IOP) is limited by poor patient adherence, low bioavailability of drug and the p

31 barrier to resistance combined with improved patient adherence may mitigate TDR increases by reducing

32 oring (n = 256, 60.8%), and errors involving patient adherence (n = 89, 21.1%) also were common.

33 tributed, by deduction, to difficulties with patient adherence or, to a lesser degree, to metabolic a

34 comparable outcomes and equivalent levels of patient adherence, patient satisfaction, and health care

35 influenced by genetic barrier, drug potency, patient adherence, pharmacological barrier, viral fitnes

36 ASRI ratings were moderately correlated with patient adherence (pharmacy), supporting the concurrent

37 In adherent patients (adherence quartiles 2-4), the median time to e

38 ward improving statin prescription rates and patient adherence should also be priorities for future r

39 ed dosing histories provide detailed data on patient adherence that can be used for efficient medicat

40 Patient adherence, the level of asthma self-management s

41 d to determine the best methods of enhancing patient adherence to a screening program.

42 gitudinal, prospective study aimed to assess patient adherence to and acceptance of once-daily tacrol

43 Patient adherence to antibiotic prophylaxis did not alte

44 Patient adherence to antihypertensive medications is not

45 re providers in facilitating improvements in patient adherence to antihypertensive medications, to pr

46 tions, to provide a framework for addressing patient adherence to antihypertensive therapy, and to pr

47 role of the healthcare provider in improving patient adherence to antihypertensive therapy.

48 rove the delivery of behavioral services and patient adherence to behavioral recommendations.

49 der and racial/ethnic gaps in the use of and patient adherence to beta-blockers, angiotensin-converti

50 ased activities were associated with greater patient adherence to dabigatran.

51 e due to pharmacologic factors or suboptimal patient adherence to drug therapy.

52 ioavailability to target tissues and lack of patient adherence to frequent dosing regimens.

53 the creation of reminder systems to improve patient adherence to medical recommendations.

54 tation and what parameters are influenced by patient adherence to nutritional care.

55 Patient adherence to prescribed antiviral therapy in hum

56 lance model that was then applied to examine patient adherence to prescribed LCD treatment programs.

57 properly managed, largely due to inadequate patient adherence to prescribed treatment regimens.

58 led brochure is an effective way to increase patient adherence to primary care physician referral for

59 ded to increase both healthcare provider and patient adherence to recommendations for retesting men a

60 ysician implementation of and secondarily on patient adherence to recommended survivorship care, amon

61 n effects on physician implementation of and patient adherence to recommended survivorship care.

62 oma exist, their efficacy is limited by poor patient adherence to the prescribed eye drop regimen.

63 issue concentrations and will require strict patient adherence to the regimen.

64 We use this model to study the influence of patient adherence to therapy and of common retreatment r

65 ately, inconvenient regimens leading to poor patient adherence to therapy, and the increasing frequen

66 Patient adherence to these medications is required for b

67 Before considering systemic treatment, patient adherence to topical treatment including skin ca

68 ore effective than medical care in promoting patient adherence to treatment and patient satisfaction.

69 Concurrent chemotherapy and patient adherence to treatment were significant mediator

70 Patients' adherence to antihypertensive drug regimens is

71 emples, and orbits and may negatively affect patients' adherence to highly active antiretroviral ther

72 gs for stroke/TIA prevention did not address patients' adherence to medication or medication targets,

73 y and daily routine were found to impact the patients' adherence to medications.

74 ients for their risk of abuse and to monitor patients' adherence to prescribed treatments.

75 inical interactions, especially by improving patients' adherence to recommended therapies.

76 ches to off-loading similarly depends on the patients' adherence to the effectiveness of pressure rel

77 tinopathy (DR) screening programs depends on patients' adherence to the timetable of follow-up eye ca

78 Prior studies, however, did not consider patients' adherence to their regimens or HAART effective

79 detection and prompt treatment may increase patients' adherence to tyrosine kinase inhibitor therapy

80 In some patients, adherence to MS treatment may be less than opt

81 Patient adherence was tracked with reasons for missed se

82 For evaluation of premenopausal patients, adherence was 63% (overmanagement, 30%) and of

83 One barrier to patient adherence with chronic topical glaucoma treatmen

84 Interventions focused on improving patient adherence with prescribed regimens and monitorin

85 Patients' adherence with posttransplant immunosuppressio

86 Patients' adherence with the antipsychotic regimen was c